Vision Disorders - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 40 pages report, published by Global Markets Direct

Keywords : Vision Disorders Therapeutic Products under Development, Key Players in Vision Disorders Therapeutics, Vision Disorders Pipeline Overview, Vision Disorders Pipeline, Vision Disorders Pipeline Assessment

Report ThumbnailSeptember-2013
Vision Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Vision Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vision Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vision Disorders. Vision Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vision Disorders.
- A review of the Vision Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vision Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vision Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vision Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Vision Disorders, H2 2013 7
  • Products under Development for Vision Disorders - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Route of Administration, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Molecule Type, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 23
  • List of Tables
  • Number of Products Under Development for Vision Disorders, H2 2013 7
  • Products under Development for Vision Disorders - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • F. Hoffmann-La Roche Ltd., H2 2013 16
  • Advanced Cell Technology, Inc., H2 2013 17
  • Pfizer Inc., H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 23
  • Vision Disorders Therapeutics - Drug Profile Updates 30
  • Vision Disorders Therapeutics - Dormant Products 34
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Vision Disorders Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Vision Disorders 7
  • Vision Disorders Therapeutics under Development by Companies 9
  • Vision Disorders Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Vision Disorders Therapeutics - Products under Development by Companies 14
  • Vision Disorders Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Vision Disorders Therapeutics Development 16
  • F. Hoffmann-La Roche Ltd. 16
  • Advanced Cell Technology, Inc. 17
  • Pfizer Inc. 18
  • Vision Disorders - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • ranibizumab - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • PF-05206388 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Ocular Programs - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Gene Therapy For Eye Diseases - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Vision Disorders Therapeutics - Drug Profile Updates 30
  • Vision Disorders Therapeutics - Dormant Products 34
  • Vision Disorders - Product Development Milestones 35
  • Featured News & Press Releases 35
  • Jun 04, 2012: Synta Presents Data Highlighting Superior Activity Of Ganetespib In Both Crizotinib-Sensitive And Resistant Models At ASCO Annual Meeting 35
  • May 24, 2012: RetroSense Therapeutics Completes Pre-IND Meeting For RST-001 35
  • Apr 17, 2012: ThromboGenics Resubmits BLA For Ocriplasmin With FDA 36
  • Mar 28, 2012: Canadian Agency For Drugs And Technologies In Health Recommends Provincial And Publicly Funded Drug Plans To Reimburse Novartis's Lucentis 36
  • Sep 14, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Diabetic Macular Edema 37
  • Aug 18, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Retinal Vein Occlusion 38
  • Appendix 39
  • Methodology 39
  • Coverage 39
  • Secondary Research 39
  • Primary Research 39
  • Expert Panel Validation 39
  • Contact Us 40
  • Disclaimer 40

Please select a license type

Share

Related Products

Global Markets DirectVision Disorders - Pipeline Review, H2 2013Product ThumbnailVision Disorders - Pipeline Review, H2 2013, Industry ReportProduct #: 113344
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved